Emergent BioSolutions (EBS) 10-Q2010 Q2 Quarterly report

Filed: 6 Aug 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: al, alt, ant, argument, Baxter, bus, cand, ccine, comp, complaint, decre, Division, duct, ear, eneral, enfo, ent, equal, equivalent, ernative, exa, formula, fourth, idate, identical, ignated, imilar, infl, informat, ing, inventive, ion, Janua, liabili, liance, lieu, linical, llion, lo, mi, millio, mple, opponent, opposition, paym, pharaceutical, plaint, poten, pro, prod, publici, purch, ra, rced, reimbu, rejudice, rsement, ry, si, signific, step, tial, timeframe, tion, trad, Transgene, ty, uct, uencing, ur, va, Virbac

Removed: appeal, biomedica, broadly, cancer, collectively, distinct, enforced, foot, guidance, historically, importing, inducing, infringed, leverage, LLC, long, PLC, predominantly, scale, smallpox, square, sued, targeting, TroVax

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

EBS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Emergent BioSolutions Inc. (the "Company") for the three and six months ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Fuad El-Hibri, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 5, 2010

/s/ Fuad El-Hibri

Fuad El-Hibri

Chief Executive Officer